BioRelix and Dalton Medicinal expand and renew research agreement

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, CEO of BioRelix, said: “We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry.

“We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines.”